Open an account

Purple Biotech

PPBT · TEL

$1.08+$0.03 (+2.86%)TodayMarket closed ·
Prev close $1.05

About PPBT

Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The company is headquartered in Rehovot, Central(Hamerkaz) and currently employs 10 full-time employees. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

Employees
10
Headquarters
Rehovot, Central(HaMerkaz)
Listed
Sep 3, 1978
Sector
Health Care
Industry
Pharmaceuticals
Website
purple-biotech.com

PPBT key statistics

Market cap
32.42M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
23.35K
Volume
24.46K
Open price
$1.05
High today
$1.09
Low today
$1.02
52 Week high
$14.10
52 Week low
$1.05

Purple Biotech (PPBT) at a glance

As of Oct 23, 2026, Purple Biotech (PPBT) shares are priced at $1.08, giving the company a market cap of 32.42M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.02 and $1.09. The current price is 5.9% above the day's low and 0.9% below its high.

Volume so far is 24.46K shares, in line with the average of 23.35K shares a day.

Over the past year Purple Biotech has ranged from $1.05 to $14.10, and now sits 0% of the way up that range.

Purple Biotech met or beat analyst EPS estimates in 0 of the last 2 quarters. In Q1 FY25 it reported -$0.17 per share against an estimate of $0.00.

The average analyst price target is $0.00, 100.0% below the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 2 analystsAvg $0.00
Low
$0.00
Now
$1.08
High
$0.00

PPBT earnings

Earnings per share, reported against the analyst estimate

Didn’t beat the estimate in any of the last 2 quarters.

  1. Q4 FY23: reported -$0.32 per share against an estimate of $0.00
  2. Q1 FY25: reported -$0.17 per share against an estimate of $0.00

PPBT news

  • Avi Kapoor

    Crude Oil Moves Higher; US Factory Orders Rise In July

  • Avi Kapoor

    Dow Surges Over 200 Points; Ollie's Bargain Outlet Shares Gain After Q2 Earnings

  • Vandana Singh

    Why Is Purple Biotech Stock Gaining Wednesday?

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.